Association Between Hypnotics and Dementia: A Mini Narrative Review

키워드

참고문헌 (50)

1. Hale L, "Sleep health : an opportunity for public health to address health equity", Annu Rev Public Health, 41, pp.81~99 (2020)
2. Palagini L, "Sleep, insomnia and mental health", J Sleep Res, 31, pp.e13628~ (2022)
3. Ma TT, "Global trends in the consumption of benzodiazepines and Z-drugs in 67 countries and regions from 2008 to 2018 : a sales data analysis", Sleep, 46, pp.zsad124~ (2023)
4. Machado FV, "More than a quarter century of the most prescribed sleeping pill : systematic review of zolpidem use by older adults", Exp Gerontol, 136, pp.110962~ (2020)
5. De Crescenzo F, "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults : a systematic review and network meta-analysis", Lancet, 400, pp.170~184 (2022)
6. Capiau A, "Therapeutic dilemmas with benzodiazepines and Z-drugs : insomnia and anxiety disorders versus increased fall risk : a clinical review", Eur Geriatr Med, 14, pp.697~708 (2023)
7. GBD 2019 Dementia Forecasting Collaborators, "Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050 : an analysis for the global burden of disease study 2019", Lancet Public Health, 7, pp.e105~e125 (2022)
8. Livingston G, "Dementia prevention, intervention, and care : 2020 report of the Lancet Commission", Lancet, 396, pp.413~446 (2020)
9. Hou JH, "Relationships of hypnotics with incident dementia and Alzheimer’s disease : a longitu dinal study and meta-analysis", J Prev Alzheimers Dis, 11, pp.117~129 (2024)
10. Tseng LY, "Benzodiazepines, z-hypnotics, and risk of dementia : special considerations of half-lives and concomitant use", Neurotherapeutics, 17, pp.156~164 (2020)
11. Osler M, "Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders : a nationwide cohort and nested case-control study", Am J Psychiatry, 177, pp.497~505 (2020)
12. Joyce G, "Benzodiaze pine use and the risk of dementia", Alzheimers Dement(N Y), 8, pp.e12309~ (2022)
13. Ghoneim MM, "Benzodiazepines and human memory : a review", Anesthesiology, 72, pp.926~938 (1990)
14. Lechin F, "Benzodiazepines : tolerability in el derly patients", Psychother Psychosom, 65, pp.171~182 (1996)
15. Torres-Bondia F, "Benzodiazepine and Z-drug use and the risk of developing de mentia", Int J Neuropsychopharmacol, 25, pp.261~268 (2022)
16. Griffin CE 3rd, "Benzodiazepine phar macology and central nervous system-mediated effects", Ochsner J, 13, pp.214~223 (2013)
17. Sartori S, "Phenobarbital use in benzodiazepine and Z-drug detoxification : a sin gle-centre 15-year observational retrospective study in clinical prac tice", Intern Emerg Med, 17, pp.1631~1640 (2022)
18. Edinoff AN, "Benzodiazepines : uses, dangers, and clinical considerations", Neurol Int, 13, pp.594~607 (2021)
19. Lader M, "Benzodiazepine harm : how can it be reduced?", Br J Clin Pharmacol, 77, pp.295~301 (2014)
20. Schifano F, "An insight into Z drug abuse and dependence : an examination of reports to the Europe an medicines agency database of suspected adverse drug reactions", Int J Neuropsychopharmacol, 22, pp.270~277 (2019)
21. Soyka M, "Treatment of benzodiazepine dependence", N Engl J Med, 376, pp.1147~1157 (2017)
22. Ryan J, "Phenotypic heteroge neity in dementia : a challenge for epidemiology and biomarker stud ies", Front Public Health, 6, pp.181~ (2018)
23. Long JM, "Alzheimer disease : an update on pathobiol ogy and treatment strategies", Cell, 179, pp.312~339 (2019)
24. Kalaria RN, "The pathology and pathophysiology of vascular dementia", Neuropharmacology, 134(Pt B), pp.226~239 (2018)
25. Matar E, "Cognitive fluctuations in Lewy body dementia : towards a pathophysiological framework", Brain, 143, pp.31~46 (2020)
26. Swift IJ, "Fluid biomarkers in frontotemporal dementia : past, present and future", J Neurol Neurosurg Psychiatry, 92, pp.204~215 (2021)
27. Arvanitakis Z, "Diagnosis and management of dementia : review", JAMA, 322, pp.1589~1599 (2019)
28. Full KM, "Associations of late-life sleep medication use with incident dementia in the atherosclerosis risk in communities study", J Gerontol A Biol Sci Med Sci, 78, pp.438~446 (2023)
29. Lilly SM, "Role of protein kinase A in GABAA recep tor dysfunction in CA1 pyramidal cells following chronic benzodiaze pine treatment", J Neurochem, 85, pp.988~998 (2003)
30. Cavaillès C, "Com plaints of daytime sleepiness, insomnia, hypnotic use, and risk of de mentia : a prospective cohort study in the elderly", Alzheimers Res Ther, 14, pp.12~ (2022)
31. Soto PL, "Allosteric modulation of GABA(A)receptor subtypes : effects on visual recognition and visuospatial working memory in rhesus monkeys", Neuropsychopharmacology, 38, pp.2315~2325 (2013)
32. Jacob TC, "Benzodi azepine treatment induces subtype-specific changes in GABA(A)re ceptor trafficking and decreases synaptic inhibition", Proc Natl Acad Sci U S A, 109, pp.18595~18600 (2012)
33. Benveniste H, "Glym phatic system function in relation to anesthesia and sleep states", Anes th Analg, 128, pp.747~758 (2019)
34. Nafti M, "Is benzodiaze pine use associated with the risk of dementia and cognitive impairment not dementia in older persons? The Canadian study of health and aging", Ann Pharmacother, 54, pp.219~225 (2020)
35. Hogan DB, "Prevalence and potential consequences of benzodiazepine use in senior citizens : results from the Canadian study of health and aging", Can J Clin Pharmacol, 10, pp.7277~ (2003)
36. Baek YH, "Un certain association between benzodiazepine use and the risk of demen tia : a cohort study", J Am Med Dir Assoc, 21, pp.201~211 (2020)
37. AlDawsari A, "Use of sedative-hypnotic medications and risk of dementia : a system atic review and meta-analysis", Br J Clin Pharmacol, 88, pp.1567~1589 (2022)
38. Lin CE, "Associ ation between concurrent antidepressant and hypnotic treatment and the risk of dementia : a nationwide cohort study", J Affect Disord, 277, pp.549~558 (2020)
39. Desmidt T, "Benzodiazepine use and brain amyloid load in nondemented older individuals : a florbetapir PET study in the multidomain Alzheimer preventive trial cohort", Neurobiol Aging, 84, pp.61~69 (2019)
40. Yuan P, "Attenuation of β-amyloid deposition and neu rotoxicity by chemogenetic modulation of neural activity", J Neurosci, 36, pp.632~641 (2016)
41. Ferreira P, "Is there a link between the use of benzodiazepines and related drugs and dementia? A system atic review of reviews", Eur Geriatr Med, 13, pp.19~32 (2022)
42. Sherman RE, "Real-world evidence—what is it and what can it tell us?", N Engl J Med, 375, pp.2293~2297 (2016)
43. Billioti de Gage S, "Is there really a link between benzodiazepine use and the risk of dementia?", Expert Opin Drug Saf, 14, pp.733~747 (2015)
44. Lapeyre-Mestre M, "Benzodiazepines, cognitive decline and dementia:a review of causality criteria from published observational studies", T herapie, 74, pp.407~419 (2019)
45. He Q, "Risk of dementia in long-term benzo diazepine users : evidence from a meta-analysis of observational stud ies", J Clin Neurol, 15, pp.9~19 (2019)
46. Penninkilampi R, "A systematic review and meta-analysis of the risk of dementia associated with benzodiazepine use, after control ling for protopathic bias", CNS Drugs, 32, pp.485~497 (2018)
47. Arfè A, "The lag-time approach improved drug-outcome as sociation estimates in presence of protopathic bias", J Clin Epidemiol, 78, pp.101~107 (2016)
48. Ettcheto M, "Benzodiazepines and related drugs as a risk factor in Al zheimer’s disease dementia", Front Aging Neurosci, 11, pp.344~ (2020)
49. Jack CR Jr, "NIA-AA research framework : toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
50. Lucey BP, "Suvorexant acutely decreases tau phosphorylation and Aβ in the hu man CNS", Ann Neurol, 94, pp.27~40 (2023)

관련 논문AI추천